HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Tolerability to terizidone (TZ) in the treatment of pulmonary tuberculosis in dialyzed patients].

Abstract
Six dialysed patients affected by tuberculosis involving the respiratory apparatus were included in the study. Antimycobacterial treatment consisted of polychemiotherapeutic combinations using terizidone (TZ). The need to resort to this drug may be explained by the need to exclude normally used drugs (R/AMP, INH, SM) due to resistance, allergy or organ meiopragia. Five patients received terizidone at a dose of 600-900 mg/day for the entire course of treatment, whereas it was necessary to abandon treatment in one patient due to the onset of depressive symptoms which then rapidly regressed following the suspension of TZ therapy. The good level of tolerance demonstrated in the 5 remaining cases confirm the inclusion of this drug in the treatment of a limited number of cases of tuberculosis in dialysed patients.
AuthorsF Galietti, G E Giorgis, A Oliaro, D Boaro, A Ardizzi, S Barberis, G M Massaglia
JournalMinerva medica (Minerva Med) 1991 Jul-Aug Vol. 82 Issue 7-8 Pg. 477-81 ISSN: 0026-4806 [Print] Italy
Vernacular TitleTollerabilità del terizidone (TZ) nel trattamento della tubercolosi polmonare in pazienti dializzati.
PMID1922892 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antitubercular Agents
  • Isoxazoles
  • Oxazoles
  • Oxazolidinones
  • terizidone
Topics
  • Adult
  • Antitubercular Agents (adverse effects, therapeutic use)
  • Female
  • Humans
  • Isoxazoles
  • Male
  • Middle Aged
  • Oxazoles (adverse effects, therapeutic use)
  • Oxazolidinones
  • Renal Dialysis
  • Tuberculosis, Pulmonary (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: